OpenAI and Ginkgo Bioworks have shown that a language model can autonomously design, execute, and learn from tens of thousands of biological experiments - cutting protein production costs by 40% in six months. The science is remarkable. The governance gap it reveals is more urgent.
The wetware computing industry is betting billions that living neurons can outperform silicon. A new organism called the neurobot, which grew its own nervous system from scratch with no evolutionary history and no instruction, may be the most radical proof of concept yet, and it raises questions that AI researchers cannot ignore.
Isomorphic Labs has a Nobel Prize-winning platform, $600 million in fresh capital, and partnerships worth up to $3 billion with Eli Lilly and Novartis. Its first AI-designed drug was supposed to enter human clinical trials by end of 2025. It didn't. What the delay reveals about the gap between computational elegance and biological proof.